Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA.

Parida L, Haferlach C, Rhrissorrakrai K, Utro F, Levovitz C, Kern W, Nadarajah N, Twardziok S, Hutter S, Meggendorfer M, Walter W, Baer C, Haferlach T.

PLoS Comput Biol. 2019 Aug 30;15(8):e1007332. doi: 10.1371/journal.pcbi.1007332. eCollection 2019 Aug.

2.

Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients.

Hartmann L, Haferlach C, Meggendorfer M, Nadarajah N, Kern W, Haferlach T, Stengel A.

Haematologica. 2019 Aug 1. pii: haematol.2019.227702. doi: 10.3324/haematol.2019.227702. [Epub ahead of print]

3.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

Höllein A, Meggendorfer M, Dicker F, Jeromin S, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Blood Adv. 2018 Nov 27;2(22):3118-3125. doi: 10.1182/bloodadvances.2018023432.

4.

A Novel Splice-Site Mutation in VEGFC Is Associated with Congenital Primary Lymphoedema of Gordon.

Nadarajah N, Schulte D, McConnell V, Martin-Almedina S, Karapouliou C, Mortimer PS, Jeffery S, Schulte-Merker S, Gordon K, Mansour S, Ostergaard P.

Int J Mol Sci. 2018 Aug 1;19(8). pii: E2259. doi: 10.3390/ijms19082259.

5.

Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses.

Vetro C, Haferlach T, Jeromin S, Stengel A, Zenger M, Nadarajah N, Baer C, Weissmann S, Kern W, Meggendorfer M, Haferlach C.

Br J Haematol. 2018 Oct;183(1):47-59. doi: 10.1111/bjh.15498. Epub 2018 Jul 18.

PMID:
30022491
6.

Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

PMID:
29795413
7.

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile.

Reidel V, Kauschinger J, Hauch RT, Müller-Thomas C, Nadarajah N, Burgkart R, Schmidt B, Hempel D, Jacob A, Slotta-Huspenina J, Höckendorf U, Peschel C, Kern W, Haferlach T, Götze KS, Jilg S, Jost PJ.

Oncotarget. 2018 Apr 3;9(25):17270-17281. doi: 10.18632/oncotarget.24775. eCollection 2018 Apr 3.

8.

Multi-GNSS PPP-RTK: From Large- to Small-Scale Networks.

Nadarajah N, Khodabandeh A, Wang K, Choudhury M, Teunissen PJG.

Sensors (Basel). 2018 Apr 3;18(4). pii: E1078. doi: 10.3390/s18041078.

9.

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

Höllein A, Jeromin S, Meggendorfer M, Fasan A, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Leukemia. 2018 Oct;32(10):2270-2274. doi: 10.1038/s41375-018-0086-0. Epub 2018 Mar 6. No abstract available.

PMID:
29568097
10.

Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing.

Stengel A, Nadarajah N, Haferlach T, Dicker F, Kern W, Meggendorfer M, Haferlach C.

Leukemia. 2018 May;32(5):1229-1238. doi: 10.1038/s41375-017-0002-z. Epub 2018 Feb 26. No abstract available.

PMID:
29479069
11.

Using reciprocity to derive the far field displacements due to buried sources and scatterers.

Rose LRF, Chiu WK, Nadarajah N, Vien BS.

J Acoust Soc Am. 2017 Nov;142(5):2979. doi: 10.1121/1.5009666.

PMID:
29195447
12.

Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.

Stengel A, Kern W, Meggendorfer M, Nadarajah N, Perglerovà K, Haferlach T, Haferlach C.

Leukemia. 2018 Feb;32(2):295-302. doi: 10.1038/leu.2017.239. Epub 2017 Jul 28.

PMID:
28751771
13.

Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells.

Daniele G, Simonetti G, Fusilli C, Iacobucci I, Lonoce A, Palazzo A, Lomiento M, Mammoli F, Marsano RM, Marasco E, Mantovani V, Quentmeier H, Drexler HG, Ding J, Palumbo O, Carella M, Nadarajah N, Perricone M, Ottaviani E, Baldazzi C, Testoni N, Papayannidis C, Ferrari S, Mazza T, Martinelli G, Storlazzi CT.

Haematologica. 2017 Jul;102(7):1204-1214. doi: 10.3324/haematol.2016.163022. Epub 2017 Apr 14.

14.

IRNSS/NavIC L5 Attitude Determination.

Zaminpardaz S, Teunissen PJ, Nadarajah N.

Sensors (Basel). 2017 Jan 30;17(2). pii: E274. doi: 10.3390/s17020274.

15.

Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations.

Vetro C, Haferlach C, Haferlach T, Zenger M, Nadarajah N, Kern W, Meggendorfer M.

Leukemia. 2016 Nov;30(11):2235-2238. doi: 10.1038/leu.2016.158. Epub 2016 May 25. No abstract available.

PMID:
27220668
16.

Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.

Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, Meggendorfer M.

Br J Haematol. 2016 Nov;175(3):419-426. doi: 10.1111/bjh.14269. Epub 2016 Jul 22.

PMID:
27447873
17.

Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards.

Haferlach T, Weber S, Konietschke R, Nadarajah N, Stengel A, Kern W, Haferlach C, Meggendorfer M.

Leukemia. 2016 Oct;30(10):2123-2125. doi: 10.1038/leu.2016.156. Epub 2016 May 25. No abstract available.

PMID:
27220669
18.

Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.

Baer C, Kern W, Koch S, Nadarajah N, Schindela S, Meggendorfer M, Haferlach C, Haferlach T.

Haematologica. 2016 Jul;101(7):830-8. doi: 10.3324/haematol.2016.145888. Epub 2016 Apr 21.

19.

Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia.

Weber S, Haferlach C, Jeromin S, Nadarajah N, Dicker F, Noël L, Zenger M, Alpermann T, Kern W, Haferlach T, Schnittger S.

Genes Chromosomes Cancer. 2016 Feb;55(2):148-57. doi: 10.1002/gcc.22321. Epub 2015 Nov 6.

PMID:
26542308
20.

Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.

Meggendorfer M, de Albuquerque A, Nadarajah N, Alpermann T, Kern W, Steuer K, Perglerová K, Haferlach C, Schnittger S, Haferlach T.

Haematologica. 2015 Dec;100(12):e487-90. doi: 10.3324/haematol.2015.127985. Epub 2015 Aug 20. No abstract available.

21.

Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

Jeromin S, Kohlmann A, Meggendorfer M, Schindela S, Perglerová K, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2016 Apr;30(4):973-6. doi: 10.1038/leu.2015.207. Epub 2015 Jul 29. No abstract available.

PMID:
26220041
22.

BRCC3 mutations in myeloid neoplasms.

Huang D, Nagata Y, Grossmann V, Radivoyevitch T, Okuno Y, Nagae G, Hosono N, Schnittger S, Sanada M, Przychodzen B, Kon A, Polprasert C, Shen W, Clemente MJ, Phillips JG, Alpermann T, Yoshida K, Nadarajah N, Sekeres MA, Oakley K, Nguyen N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Miyano S, Haferlach C, Kern W, Haferlach T, Du Y, Ogawa S, Makishima H.

Haematologica. 2015 Aug;100(8):1051-7. doi: 10.3324/haematol.2014.111989. Epub 2015 May 22.

23.

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.

Alpermann T, Haferlach C, Eder C, Nadarajah N, Meggendorfer M, Kern W, Haferlach T, Schnittger S.

Leuk Res. 2015 Mar;39(3):265-72. doi: 10.1016/j.leukres.2014.11.026. Epub 2014 Dec 16.

PMID:
25592059
24.

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, Alpermann T, Kohlmann A, Kern W, Haferlach C, Schnittger S.

Haematologica. 2015 Apr;100(4):e125-7. doi: 10.3324/haematol.2014.119032. Epub 2014 Dec 19. No abstract available.

25.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, Kuznia S, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2015 Mar;29(3):660-7. doi: 10.1038/leu.2014.243. Epub 2014 Aug 11.

PMID:
25110071
26.

Integrated GNSS attitude determination and positioning for direct geo-referencing.

Nadarajah N, Paffenholz JA, Teunissen PJ.

Sensors (Basel). 2014 Jul 17;14(7):12715-34. doi: 10.3390/s140712715.

27.

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.

Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, Fasan A, Kohlmann A, Meggendorfer M, Haferlach C, Kern W, Haferlach T, Schnittger S.

Blood Cancer J. 2014 Jan 10;4:e173. doi: 10.1038/bcj.2013.71.

28.

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2014 Jul;28(7):1449-58. doi: 10.1038/leu.2014.4. Epub 2014 Jan 9.

PMID:
24402164
29.

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Kohlmann A, Miyano S, Haferlach C, Kern W, Ogawa S.

Leukemia. 2014 Feb;28(2):241-7. doi: 10.1038/leu.2013.336. Epub 2013 Nov 13.

30.

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.

Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, Roller A, Kern W, Haferlach C, Schnittger S, Haferlach T.

Leukemia. 2014 Jan;28(1):129-37. doi: 10.1038/leu.2013.239. Epub 2013 Aug 20.

PMID:
23958918
31.

BeiDou inter-satellite-type bias evaluation and calibration for mixed receiver attitude determination.

Nadarajah N, Teunissen PJ, Raziq N.

Sensors (Basel). 2013 Jul 22;13(7):9435-63. doi: 10.3390/s130709435.

32.

CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.

Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S.

Br J Haematol. 2013 Jun;161(5):649-58. doi: 10.1111/bjh.12297. Epub 2013 Mar 25.

PMID:
23521373
33.

Landmark analysis of DNMT3A mutations in hematological malignancies.

Roller A, Grossmann V, Bacher U, Poetzinger F, Weissmann S, Nadarajah N, Boeck L, Kern W, Haferlach C, Schnittger S, Haferlach T, Kohlmann A.

Leukemia. 2013 Jul;27(7):1573-8. doi: 10.1038/leu.2013.65. Epub 2013 Mar 1. No abstract available.

PMID:
23519389
34.

Next-generation sequencing - feasibility and practicality in haematology.

Kohlmann A, Grossmann V, Nadarajah N, Haferlach T.

Br J Haematol. 2013 Mar;160(6):736-53. doi: 10.1111/bjh.12194. Epub 2013 Jan 7. Review.

PMID:
23294427
35.

Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma.

Grossmann V, Bacher U, Artusi V, Kohlmann A, Nadarajah N, Kern W, Schnittger S, Haferlach T, Haferlach C.

Blood Cancer J. 2012 Aug 31;2:e85. doi: 10.1038/bcj.2012.33. No abstract available.

36.

Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.

Bacher U, Schnittger S, Macijewski K, Grossmann V, Kohlmann A, Alpermann T, Kowarsch A, Nadarajah N, Kern W, Haferlach C, Haferlach T.

Blood. 2012 May 17;119(20):4719-22. doi: 10.1182/blood-2011-12-395574. Epub 2012 Mar 22.

PMID:
22442349
37.

Landscape of TET2 mutations in acute myeloid leukemia.

Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A.

Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25.

PMID:
22116554
38.

Diffusion-weighted imaging in acute demyelinating myelopathy.

Zecca C, Cereda C, Wetzel S, Tschuor S, Staedler C, Santini F, Nadarajah N, Bassetti CL, Gobbi C.

Neuroradiology. 2012 Jun;54(6):573-8. doi: 10.1007/s00234-011-0907-6. Epub 2011 Jul 9.

PMID:
21743997
39.

Composition of activated sludge settling and planktonic bacterial communities treating industrial effluent and their correlation to settling problems.

Nadarajah N, Allen DG, Fulthorpe RR.

Appl Microbiol Biotechnol. 2010 Nov;88(5):1205-14. doi: 10.1007/s00253-010-2829-3. Epub 2010 Aug 25.

PMID:
20737270
40.

Effect of the degree and duration of early dietary amino acid restrictions on subsequent and overall pig performance and physical and sensory characteristics of pork.

Kamalakar RB, Chiba LI, Divakala KC, Rodning SP, Welles EG, Bergen WG, Kerth CR, Kuhlers DL, Nadarajah NK.

J Anim Sci. 2009 Nov;87(11):3596-606. doi: 10.2527/jas.2008-1609. Epub 2009 Jul 2.

PMID:
19574567
41.

Effects of transient temperature conditions on the divergence of activated sludge bacterial community structure and function.

Nadarajah N, Allen DG, Fulthorpe RR.

Water Res. 2007 Jun;41(12):2563-71. Epub 2007 Apr 19.

PMID:
17448516
42.

Laboratory evidence of MTBE biodegradation in Borden aquifer material.

Schirmer M, Butler BJ, Church CD, Barker JF, Nadarajah N.

J Contam Hydrol. 2003 Feb;60(3-4):229-49.

PMID:
12504361
43.

Enhanced transformation of polycyclic aromatic hydrocarbons using a combined Fenton's reagent, microbial treatment and surfactants.

Nadarajah N, Van Hamme J, Pannu J, Singh A, Ward O.

Appl Microbiol Biotechnol. 2002 Aug;59(4-5):540-4. Epub 2002 Jul 9.

PMID:
12172623
44.

Degradation of carbon tetrachloride in the presence of iron and sulphur containing compounds.

Lipczynska-Kochany E, Harms S, Milburn R, Sprah G, Nadarajah N.

Chemosphere. 1994 Oct;29(7):1477-89.

PMID:
22454977
45.

Leptospirosis risk in public cleansing and sewer workers.

Chan OY, Chia SE, Nadarajah N, Sng EH.

Ann Acad Med Singapore. 1987 Oct;16(4):586-90.

PMID:
3446001

Supplemental Content

Loading ...
Support Center